Mostra el registre parcial de l'element
dc.contributor.author | Lerma-Chippirraz, Elisabet |
dc.contributor.author | Güerri Fernández, Roberto |
dc.contributor.author | Villar García, Judit |
dc.contributor.author | González Mena, Alicia |
dc.contributor.author | Guelar Grinberg, Ana |
dc.contributor.author | Montero, M. |
dc.contributor.author | Sorli Redó, M. Luisa |
dc.contributor.author | Calzado, Sonia |
dc.contributor.author | Horcajada Gallego, Juan Pablo |
dc.contributor.author | Díez Pérez, Adolfo |
dc.contributor.author | Knobel Freud, Hernando |
dc.date.accessioned | 2017-03-16T07:59:11Z |
dc.date.available | 2017-03-16T07:59:11Z |
dc.date.issued | 2016 |
dc.identifier.citation | Lerma-Chippirraz E, Güerri-Fernández R, Villar García J, González Mena A, Guelar Grinberg A, Montero MM. Validation Protocol of Vitamin D Supplementation in Patients with HIV-Infection. AIDS Res Treat. 2016;2016:5120831 |
dc.identifier.issn | 2090-1240 |
dc.identifier.uri | http://hdl.handle.net/10230/28244 |
dc.description.abstract | Hypovitaminosis D and secondary hyperparathyroidism are frequent among HIV-infected patients. As there are no data about the best supplementation therapy both in treatment and in maintenance, we conducted an observational study of 300 HIV-infected patients for whom vitamin D and parathormone (PTH) had been measured in order to validate a protocol of vitamin D supplementation in patients with HIV-infection. Patients with vitamin D deficiency (defined as 25(OH)D < 10 ng/mL), insufficiency (defined as 25(OH)D < 20 ng/mL), or hyperparathyroidism (PTH > 65 pg/mL) were supplemented with cholecalciferol 16.000IU (0.266 mg) weekly (if deficiency) or fortnightly (if insufficiency or high PTH levels). Rates of normalization of 25(OH)D (levels above 20 ng/mL) and PTH levels (<65 pg/mL) were analyzed. Multivariate analysis of factors related to normalization was carried out. With a median follow-up of 2 years, 82.1% of patients with deficiency and 83.9% of cases with insufficiency reached levels above 20 ng/mL. However, only 67.2% of individuals with hyperparathyroidism at baseline reached target levels (<65 pg/mL). Independent factors for not achieving PTH objective were tenofovir (TDF) and protease inhibitors use. In HIV-infected patients with hypovitaminosis, the protocol of cholecalciferol supplementation normalized vitamin D levels regardless of antiretroviral regimen in a high proportion of patients but it was less effective to correct hyperparathyroidism. |
dc.format.mimetype | application/pdf |
dc.language.iso | eng |
dc.publisher | Hindawi |
dc.relation.ispartof | AIDS Research and Treatment. 2016;2016:5120831 |
dc.rights | Copyright © 2016 Elisabet Lerma-Chippirraz et al. This is an open access article distributed under https://creativecommons.org/licenses/by/4.0/, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ |
dc.subject.other | VIH (Virus) -- Tractament |
dc.subject.other | Vitamines |
dc.title | Validation Protocol of Vitamin D Supplementation in Patients with HIV-Infection. |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | http://dx.doi.org/10.1155/2016/5120831 |
dc.rights.accessRights | info:eu-repo/semantics/openAccess |
dc.type.version | info:eu-repo/semantics/publishedVersion |